Clinical Trial Update: An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data [Phase 3]

View source ↗

Summary

An open-label, rollover Phase 3 study of Gevokizumab in uveitis to assess long-term safety has been terminated, with data collection focused on safety prior to …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveitis

Drugs mentioned

• Gevokizumab (gevokizumab)

Snippet

Sponsor: XOMA (US) LLC | Conditions: Uveitis | Phase 3 | Status: TERMINATED